SGLT-2 DM Combi Benefit Expansion Expected to be applied

from April

Ministry of Health and Welfare recently accepted

Expansion of reimbursement for the combination of SGLT-2 diabetes treatment and other treatments is expected to be applied from April.

 

It is said that the government accepted the wage increase after receiving details of voluntary reductions from related companies earlier this month.

 

According to the industry on the 20th, it was reported that the Ministry of Health and Welfare, which is discussing the expansion of the combined benefit of SGLT-2 diabetes treatment, has set up a plan to apply for the benefit in April.

 

Currently, the concomitant benefit drugs being discussed are triple therapy such as metformin + SGLT-2 + DPP-4, metformin + SGLT-2 + TZD, and some SGLT-2 items + sulfonylurea or insulin combination therapy.

 

The Ministry of Health and Welfare estimates that these combined benefits will cost tens of billions of won.

 

The Ministry of Health and Welfare induced 11 companies with benefits expansion drugs to voluntarily lower the maximum amount in order to share finances as it requires enormous financial resources.

 

However, in November of last year, the government received a voluntary cut rate and started an analysis of the fiscal impact, but there was no further progress as it exceeded the expected range.

 

As a result, by the beginning of this month, the voluntary reduction rate was once again received, but this time it is interpreted that the financial range was satisfied.

 

It is said that the companies have expanded the reduction rate and submitted it to the Ministry of Health and Welfare.

 

For drugs that are voluntarily reduced to expand the range of use, benefits can be applied quickly because only a quality supply contract is required with the NHIS, bypassing the review by the Drug Evaluation Committee of the HIRA.

 

In response, the government is said to be planning to apply for benefits from April through a report to the deliberation committee next month.

 

As related combination drugs are currently waiting for approval, it is expected that the expansion of the combination benefit will become a new trend in the diabetes treatment market.